Oncodesign Precision Medicine Société anonyme (FRA:ZR8)

Market Cap	6.04M -12.6%
Revenue (ttm)	1.81M +10.9%
Net Income	5.48M
EPS	0.30
Shares Out	n/a
PE Ratio	1.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2850
Previous Close	0.2890
Day's Range	0.2850 - 0.2890
52-Week Range	0.2790 - 0.7800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2026

About FRA:ZR8

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ZR8

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error